Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Pharmacogenetic Study to Evaluate the Efficacy and Safety of FOLFIRI Schedule With High Doses of Irinotecan (FOLFIRI-AD) in Patients With Metastatic Colorectal Cancer According to UGT1A Genotype 1.

NCT01639326 is registered in ClinicalTrials.gov with Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau as lead sponsor.

NCT NCT01639326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01639326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Pharmacogenetic Study to Evaluate the Efficacy and Safety of FOLFIRI Schedule With High Doses of Irinotecan (FOLFIRI-AD) in Patients With Metastatic Colorectal Cancer According to UGT1A Genotype 1.
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2012
Completion date
September 30, 2018
Enrollment
96 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer